Echo Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $0.03
50-Day Range
MA: $0.04
52-Week Range
Now: $0.03
Volume4,680 shs
Average Volume75,224 shs
Market Capitalization$356,160.00
P/E RatioN/A
Dividend YieldN/A
Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.
Echo Therapeutics logo

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:ECTE
Previous SymbolNASDAQ:ECTE
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$356,160.00
Next Earnings DateN/A
OptionableNot Optionable


News for Echo Therapeutics Inc
November 19, 2020 |  markets.businessinsider.com
Echo Therapeutics (ECTE) Stock
August 1, 2020 |  markets.businessinsider.com
Echo Therapeutics Inc
October 11, 2019 |  markets.ft.com
3 Stocks Pushing The Drugs Industry Lower
October 9, 2019 |  www.thestreet.com
See More Headlines


Overall MarketRank

0.54 out of 5 stars

Medical Sector

1482nd out of 2,019 stocks

Electromedical Equipment Industry

41st out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ECTE News and Ratings via Email

Sign-up to receive the latest news and ratings for ECTE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Echo Therapeutics (OTCMKTS:ECTE) Frequently Asked Questions

What stocks does MarketBeat like better than Echo Therapeutics?

Wall Street analysts have given Echo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Echo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Echo Therapeutics?

Echo Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 10,500 shares, a drop of 37.1% from the February 28th total of 16,700 shares. Based on an average daily trading volume, of 82,400 shares, the days-to-cover ratio is presently 0.1 days.
View Echo Therapeutics' Short Interest

How were Echo Therapeutics' earnings last quarter?

Echo Therapeutics, Inc. (OTCMKTS:ECTE) posted its earnings results on Friday, August, 12th. The medical device company reported ($0.82) earnings per share (EPS) for the quarter. During the same period in the prior year, the business posted ($0.97) EPS.
View Echo Therapeutics' earnings history

How has Echo Therapeutics' stock price been impacted by COVID-19?

Echo Therapeutics' stock was trading at $0.0070 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ECTE stock has increased by 357.1% and is now trading at $0.0320.
View which stocks have been most impacted by COVID-19

Who are Echo Therapeutics' key executives?

Echo Therapeutics' management team includes the following people:
  • Mr. Alan W. Schoenbart CPA, Chief Exec. Officer, Chief Financial Officer and Director (Age 62, Pay $260k)

Who are some of Echo Therapeutics' key competitors?

What other stocks do shareholders of Echo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Echo Therapeutics investors own include Biocept (BIOC), DexCom (DXCM), Rexahn Pharmaceuticals (REXN), Acer Therapeutics (ACER), Athersys (ATHX), CytRx (CYTR), Glu Mobile (GLUU), InterCloud Systems (ICLD), NetApp (NTAP) and ReShape Lifesciences (RSLS).

What is Echo Therapeutics' stock symbol?

Echo Therapeutics trades on the OTCMKTS under the ticker symbol "ECTE."

How do I buy shares of Echo Therapeutics?

Shares of ECTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Echo Therapeutics' stock price today?

One share of ECTE stock can currently be purchased for approximately $0.03.

How much money does Echo Therapeutics make?

Echo Therapeutics has a market capitalization of $356,160.00.

How many employees does Echo Therapeutics have?

Echo Therapeutics employs 19 workers across the globe.

What is Echo Therapeutics' official website?

The official website for Echo Therapeutics is www.echotx.com.

Where are Echo Therapeutics' headquarters?

Echo Therapeutics is headquartered at 99 WOOD AVENUE SOUTH SUITE 302, ISELIN NJ, 08830.

How can I contact Echo Therapeutics?

Echo Therapeutics' mailing address is 99 WOOD AVENUE SOUTH SUITE 302, ISELIN NJ, 08830. The medical device company can be reached via phone at 732-549-0128 or via email at [email protected]

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.